Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Cancer Lett. 2015 Dec 3;373(1):88–96. doi: 10.1016/j.canlet.2015.11.029

Fig. 4.

Fig. 4

CPA + CpG-1826 treatment increases immune cell markers identified by qPCR. GL261 tumors from treated and untreated mice were excised on treatment day 12 (Fig. 2) and analyzed for the indicated tumor-infiltrating immune cell markers by qPCR. Data are shown for: untreated, n = 11; CpG-1826, n = 7; 45 mg/kg CPA, n = 7; 45 mg/kg CPA + CpG-1826, n = 8; 90 mg/kg CPA, n = 8; and 90 mg/kg CPA + CpG-1826, n = 5 mice per group. Significance is indicated by: *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001; combination treatment groups were compared to CpG-1826 alone (dagger symbol) or CPA at the appropriate dose (double-dagger) by two-tailed t-test, p < 0.05 or one-tailed t-test (double quotation marks), p < 0.05.